GlassScriptPhysician profile
Shawnya A Gore
NPI 1043206782
$3,001.20
in general payments reported to CMS, 2019-2025
34 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,098 · 2022: $132 · 2023: $417 · 2024: $640 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.96 | 2019-2025 | |
| Novo Nordisk INC | $437.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $380.44 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $302.98 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $187.31 | 2019-2023 | Veozah |
| Phathom Pharmaceuticals, INC. | $146.39 | 2024-2025 | Voquezna |
| Pfizer INC. | $142.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $88.67 | 2019 | |
| Amgen INC. | $88.34 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $78.91 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.45 | 2019 | |
| Exact Sciences Corporation | $64.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.88 | 2019-2023 | Tradjenta, Synjardy, Jardiance |
| Shield Therapeutics INC | $36.90 | 2023-2024 | Accrufer |
| Boston Scientific Corporation | $35.50 | 2025 | Watchman Flx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.49 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $35.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $33.22 | 2019 | |
| Genentech USA, INC. | $29.85 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $29.11 | 2023 | Abilify Maintena, Rexulti |
| Idorsia Pharmaceuticals US INC | $20.93 | 2022 | |
| Nevro Corp. | $19.83 | 2024 | Senza |
| Medicure Pharma INC. | $17.95 | 2025 | Zypitamag |
| Corcept Therapeutics | $16.83 | 2025 | Korlym |
| Vifor Pharma, INC. | $16.65 | 2019 | |
| Daiichi Sankyo INC. | $16.46 | 2025 | Injectafer |
| Neurocrine Biosciences, INC. | $16.36 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $15.55 | 2022 | |
| Dexcom, INC. | $15.25 | 2024 | Dexcom G6 Transmitter |
| Amag Pharmaceuticals, INC. | $15.25 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.50 | 2025 | Xifaxan |
| Shire North American Group INC | $12.63 | 2019 | |
| Amarin Pharma, INC. | $11.54 | 2019 | |
| Eisai INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawnya Gore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.